{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:50:44Z","timestamp":1789339844215,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Cancer Center","award":["26-A-4"],"award-info":[{"award-number":["26-A-4"]}]},{"name":"National Cancer Center","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18ck0106439"],"award-info":[{"award-number":["JP18ck0106439"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s12185-020-02832-x","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T10:38:22Z","timestamp":1580812702000},"page":"686-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy"],"prefix":"10.1007","volume":"111","author":[{"given":"Akihiko","family":"Sawaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7094-6489","authenticated-orcid":false,"given":"Motoko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Tawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"2832_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/PL00007853","volume":"249","author":"S Quasthoff","year":"2002","unstructured":"Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9\u201317.","journal-title":"J Neurol"},{"key":"2832_CR2","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s00520-014-2255-7","volume":"22","author":"F Mols","year":"2014","unstructured":"Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22:2261\u20139.","journal-title":"Support Care Cancer"},{"key":"2832_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12185-019-02681-3","volume":"110","author":"K Ohmachi","year":"2019","unstructured":"Ohmachi K. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5-diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). Int J Hematol. 2019;110:131\u201346.","journal-title":"Int J Hematol"},{"key":"2832_CR4","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1200\/JCO.2011.34.8508","volume":"29","author":"T Watanabe","year":"2011","unstructured":"Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, et al. Phase II\/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin\u2019s lymphoma: JCOG 0203 trial. J Clin Oncol. 2011;29:3990\u20138.","journal-title":"J Clin Oncol"},{"key":"2832_CR5","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","volume":"22","author":"MS Czuczman","year":"2004","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin\u2019s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711\u20136.","journal-title":"J Clin Oncol"},{"key":"2832_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12185-019-02655-5","volume":"110","author":"K Izutsu","year":"2019","unstructured":"Izutsu K. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-1. Follicular lymphoma (FL). Int J Hematol. 2019;110:11\u20139.","journal-title":"Int J Hematol"},{"key":"2832_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817\u201326.","journal-title":"Lancet"},{"key":"2832_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22\u201332.","journal-title":"Blood"},{"key":"2832_CR9","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","volume":"378","author":"C Recher","year":"2011","unstructured":"Recher C, Coiffier B, Haioun C, Molina TJ, Ferme C, Casasnovas O, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378:1858\u201367.","journal-title":"Lancet"},{"key":"2832_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"2832_CR11","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/annonc\/mdq619","volume":"22","author":"K Ohmachi","year":"2011","unstructured":"Ohmachi K, Tobinai K, Kobayashi Y, Itoh K, Nakata M, Shibata T, et al. Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin\u2019s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol. 2011;22:1382\u201391.","journal-title":"Ann Oncol"},{"key":"2832_CR12","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s11136-010-9670-0","volume":"19","author":"BJ Kim","year":"2010","unstructured":"Kim BJ, Park HR, Roh HJ, Jeong DS, Kim BS, Park KW, et al. Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res. 2010;19:1097\u2013103.","journal-title":"Qual Life Res"},{"key":"2832_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/BF03259853","volume":"1","author":"SS Legha","year":"1986","unstructured":"Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol. 1986;1:421\u20137.","journal-title":"Med Toxicol"},{"key":"2832_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/pbc.21435","volume":"50","author":"JL Renbarger","year":"2008","unstructured":"Renbarger JL, McCammack KC, Rouse CE, Hall SD. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer. 2008;50:769\u201371.","journal-title":"Pediatr Blood Cancer"},{"key":"2832_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2015.0894","volume":"313","author":"B Diouf","year":"2015","unstructured":"Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313:815\u201323.","journal-title":"JAMA"},{"key":"2832_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/FPC.0000000000000191","volume":"26","author":"A Gutierrez-Camino","year":"2016","unstructured":"Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, Echebarria-Barona A, Zabalza I, Ruiz I, et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genomics. 2016;26:100\u20132.","journal-title":"Pharmacogenet Genomics"},{"key":"2832_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/cpt.506","volume":"101","author":"W Stock","year":"2017","unstructured":"Stock W, Diouf B, Crews KR, Pei D, Cheng C, Laumann K, et al. An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther. 2017;101:391\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"2832_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/FPC.0000000000000345","volume":"28","author":"NK Zgheib","year":"2018","unstructured":"Zgheib NK, Ghanem KM, Tamim H, Aridi C, Shahine R, Tarek N, et al. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics. 2018;28:189\u201395.","journal-title":"Pharmacogenet Genomics"},{"key":"2832_CR19","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1038\/emboj.2009.161","volume":"28","author":"N Oshimori","year":"2009","unstructured":"Oshimori N, Li X, Ohsugi M, Yamamoto T. Cep72 regulates the localization of key centrosomal proteins and proper bipolar spindle formation. EMBO J. 2009;28:2066\u201376.","journal-title":"EMBO J"},{"key":"2832_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.clinthera.2015.10.017","volume":"38","author":"M Bosilkovska","year":"2016","unstructured":"Bosilkovska M, Ing Lorenzini K, Uppugunduri CR, Desmeules J, Daali Y, Escher M. Severe vincristine-induced neuropathic pain in a CYP3A5 nonexpressor with reduced CYP3A4\/5 activity: case study. Clin Ther. 2016;38:216\u201320.","journal-title":"Clin Ther"},{"key":"2832_CR21","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/cpt.1324","volume":"105","author":"L Li","year":"2019","unstructured":"Li L, Sajdyk T, Smith EML, Chang CW, Li C, Ho RH, et al. Genetic variants associated with vincristine-induced peripheral neuropathy in two populations of children with acute lymphoblastic leukemia. Clin Pharmacol Ther. 2019;105:1421\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"2832_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bjh.15428","volume":"185","author":"D Azoulay","year":"2019","unstructured":"Azoulay D, Nasser R, Sharon R, Simanovich L, Akria L, Shaoul E, et al. Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine-induced peripheral neuropathy in patients with lymphoma. Br J Haematol. 2019;185:175\u20137.","journal-title":"Br J Haematol"},{"key":"2832_CR23","first-page":"215","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition)","author":"Mature B-cell neoplasms","year":"2017","unstructured":"Mature B-cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition). Lyon: IARC; 2017. p. 215\u2013344."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-020-02832-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:27:33Z","timestamp":1611707253000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-020-02832-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["2832"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02832-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"12 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AS, KM, MY, and IT report grants from Astellas Pharma, Kyowa Kirin, Ono Pharmaceutical, and Takeda Pharmaceutical, outside the submitted work. NK reports honoraria from Chugai Pharmaceutical and Celgene, and grants from Astellas Pharma, Kyowa Kirin, Ono Pharmaceutical, and Takeda Pharmaceutical, outside the submitted work. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}